% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schmche:286750,
      author       = {T. Schmäche and J. Fohgrub and A. Klimova and K.
                      Laaber$^*$ and S. Drukewitz and F. Merboth and A. Hennig and
                      T. Seidlitz and F. Herbst-Nowrouzi$^*$ and F. Baenke and
                      A.-M. Ada and T. Groß$^*$ and C. Wenzel and C. Ball$^*$ and
                      C. Praetorius and T. Schmidt and B. Ringelband-Schilling and
                      R. Koschny and A. Stenzinger and I. Roeder and D. Jäger$^*$
                      and S. Zeissig and T. Welsch and D. Aust and H. Glimm$^*$
                      and G. Folprecht and J. Weitz and G. M. Haag$^*$ and D. E.
                      Stange},
      title        = {{S}tratifying esophago-gastric cancer treatment using a
                      patient-derived organoid-based threshold.},
      journal      = {Molecular cancer},
      volume       = {23},
      number       = {1},
      issn         = {1476-4598},
      address      = {London},
      publisher    = {Biomed Central},
      reportid     = {DKFZ-2024-00082},
      pages        = {10},
      year         = {2024},
      note         = {#LA:D120# / Correspondence},
      abstract     = {This study sought to determine the value of patient-derived
                      organoids (PDOs) from esophago-gastric adenocarcinoma (EGC)
                      for response prediction to neoadjuvant chemotherapy
                      (neoCTx).Endoscopic biopsies of patients with locally
                      advanced EGC (n = 120) were taken into culture and PDOs
                      expanded. PDOs' response towards the single substances of
                      the FLOT regimen and the combination treatment were
                      correlated to patients' pathological response using tumor
                      regression grading. A classifier based on FLOT response of
                      PDOs was established in an exploratory cohort (n = 13) and
                      subsequently confirmed in an independent validation cohort
                      (n = 13).EGC PDOs reflected patients' diverse responses to
                      single chemotherapeutics and the combination regimen FLOT.
                      In the exploratory cohort, PDOs response to single 5-FU and
                      FLOT combination treatment correlated with the patients'
                      pathological response (5-FU: Kendall's τ = 0.411, P =
                      0.001; FLOT: Kendall's τ = 0.694, P = 2.541e-08). For FLOT
                      testing, a high diagnostic precision in receiver operating
                      characteristic (ROC) analysis was reached with an AUCROC of
                      0.994 (CI 0.980 to 1.000). The discriminative ability of
                      PDO-based FLOT testing allowed the definition of a
                      threshold, which classified in an independent validation
                      cohort FLOT responders from non-responders with high
                      sensitivity $(90\%),$ specificity $(100\%)$ and accuracy
                      $(92\%).In$ vitro drug testing of EGC PDOs has a high
                      predictive accuracy in classifying patients' histological
                      response to neoadjuvant FLOT treatment. Taking into account
                      the high rate of successful PDO expansion from biopsies, the
                      definition of a threshold that allows treatment
                      stratification paves the way for an interventional trial
                      exploring PDO-guided treatment of EGC patients.},
      subtyp        = {Letter},
      keywords     = {Gastric cancer (Other) / Patient-derived organoids (Other)
                      / Personalized medicine (Other) / Response prediction
                      (Other)},
      cin          = {B280 / DD01 / D120},
      ddc          = {570},
      cid          = {I:(DE-He78)B280-20160331 / I:(DE-He78)DD01-20160331 /
                      I:(DE-He78)D120-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38200602},
      doi          = {10.1186/s12943-023-01919-3},
      url          = {https://inrepo02.dkfz.de/record/286750},
}